Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Special Products, part of Fluor Corp., is a Dutch company. The firm manufactures systems and components. It was acquired by Stork BV, part of Fluor Corp. since February 2008, from Waertsila Nsd Nederland on May 01, 1999.

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Veriton Pharma Ltd. engages in the development and manufacture of pharmaceutical products which focuses in the fields of epilepsy, neurology and rare paediatric conditions. It offers Epistatus, paediatric medicine, and inborn errors of metabolism medicine. The company was founded by Graham March in 1997 and is headquartered in Weybridge, the United Kingdom.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Akroswiss is a Swiss pharmaceutical company that is developing new intranasal formulations in CNS.

Jiangsu Enhua Pharmaceutical Co., Ltd. is strategically positioned in the central nervous drug market, mainly engaged in the development, production and sales of central nervous system drugs. It is a company specializing in the market segment of central nervous drugs. The main categories include anesthesia and spirit. Class and Neurology, through years of unremitting efforts in product development, production and service, the company has established a complete series of central nervous system drug products and marketing network, and strive to build an important domestic producer and sales of central nervous system drugs. Business.

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Troikaa Pharmaceuticals Ltd. is an Indian private company located in Ahmedabad. The firm manufactures and supplies pharmaceutical products. It was founded in 1994.

EMS is the leading pharmaceutical company in Brazil. Established since 45 years and with 100% national capital, the company has two industrial plants strategically placed in São Bernardo do Campo and Hortolândia, in the state of São Paulo.With a work based on daring, simplicity, excellence and responsibility, the company reached the top of the ranking, but not by chance.The strength of the brand belongs on the constant investments in structure and research, in the continuous expansion of the products line and in the pioneer attitude. As the first Brazilian laboratory to export medicine products to Europe and to produce, in the country, medicine products in fractioned packing and generics, EMS is definitively reinventing the pharmaceutical market.

Microspectrum technology, formerly known as Shanghai Microspectrum Analysis and Testing Center, was established in 2008. Headquartered in Shanghai, it has branches in Guangzhou, Suzhou, Qingdao, Chengdu and other places. It is a professional comprehensive technology service provider in the field of materials and chemistry. Microspectrum technology has microspectrum analysis, microspectrum detection and other brands. The business covers materials, chemistry, environmental protection, food and other fields, and provides comprehensive solutions such as composition analysis, product development, product testing, instrument testing, and intellectual property consulting for problems encountered by enterprises in product research and development, quality control, and intellectual property rights. Composition analysis: assist in product development or improvement, quality control or industrial diagnosis, composition analysis, and major service projects Product development: entrusted development of new products, complete formula production process, quality control plan, raw materials, equipment purchase plan Instrument test: element ion, large instrument test, personalized service Product testing: product performance evaluation and quality evaluation Intellectual property consulting: provide technology related consulting programs, research and development ideas and innovation achievements protection, patent consulting and planning, and science and technology project application consulting

Fuan Pharmaceutical Group Chongqing Libang Drug Development Co., Ltd., established on 2008-03-28, Business scope includes drug development and research;Drug technology transfer and drug technology consulting;Chemical API,Research and development and technology transfer of preparations and pharmaceutical and chemical intermediates,technical consulting.(law,Prohibited and restricted operations prohibited by laws and regulations;law,regulations,The State Council stipulates that pre-approval is required,Do not operate without approval).

Neon Laboratories specializes in manufacturing formulations, oral solid dosage form, liquid injection, and dry powder injection.

Develops prescription drugs for mild to moderate pain relief

B. Braun Melsungen AG manufactures and distributes pharmaceutical products and medical equipment. Its products are used in the treatment of degenerative spinal diseases, diabetes management, nutritional therapy, extracorporeal blood treatment, laparoscopy, neurosurgery, wound management, and urology. The company was founded on June 23, 1839 and is headquartered in Melsungen, Germany.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Ouro Fino Participa����es e Empreendimentos SA, a subsidiary of Ouro Fino Sa��de Animal Participa����es SA, is a Brazilian company that manufactures household cleaning products, agricultural chemicals and other chemical products.